Newsfeeds - Spark Newswire

2 minute read

Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs

Today, 9:10 PM

New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per patient monthly when it launched in 2021.

AMGN

1 minute read

Morgan Stanley Maintains Equal-Weight on Mirati Therapeutics, Lowers Price Target to $50

By Benzinga Newsdesk

Today, 9:10 PM

Morgan Stanley analyst Michael Ulz maintains Mirati Therapeutics (NASDAQ:MRTX) with a Equal-Weight and lowers the price target from $60 to $50.

MRTX

5 minute read

Biogen’s 2nd Alzheimer’s Antibody, BeiGene’s Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors

By Shanthi Rexaline

Today, 9:10 PM

Biopharma stocks were not immune to the broader market downturn seen for much of 2022.

BGNE

1 minute read

Morgan Stanley Maintains Equal-Weight on Mirati Therapeutics, Lowers Price Target to $60

By Benzinga Newsdesk

Today, 9:10 PM

Morgan Stanley analyst Michael Ulz maintains Mirati Therapeutics (NASDAQ:MRTX) with a Equal-Weight and lowers the price target from $70 to $60.

MRTX

1 minute read

SVB Leerink Maintains Outperform on Mirati Therapeutics, Lowers Price Target to $75

By Benzinga Newsdesk

Today, 9:10 PM

SVB Leerink analyst Andrew Berens maintains Mirati Therapeutics (NASDAQ:MRTX) with a Outperform and lowers the price target from $85 to $75.

MRTX

3 minute read

Why Quotient Shares Are Trading Lower By More Than 48%; Here Are 37 Stocks Moving Premarket

By Lisa Levin

Today, 9:10 PM

Gainers Netcapital Inc. (NASDAQ: NCPL) shares rose 91.3% to $2.65 in pre-market trading following Q2 results. Netcapital posted Q2 earnings of $0.04 per share on sales of $1.78 million.

ABCL

1 minute read

Another Competitor For Amgen As FDA Approves Mirati Therapeutics’ KRAS Inhibitor For Lung Cancer Setting

By Vandana Singh

Today, 9:10 PM

The FDA granted accelerated approval to Mirati Therapeutics Inc (NASDAQ:MRTX) Krazati (adagrasib), a targeted treatment option for adult patients with KRASG12C-mutated locally…

MRTX

1 minute read

Piper Sandler Maintains Overweight on Mirati Therapeutics, Raises Price Target to $87

By Benzinga Newsdesk

Today, 9:10 PM

Piper Sandler analyst Swapnil Malekar maintains Mirati Therapeutics (NASDAQ:MRTX) with a Overweight and raises the price target from $84 to $87.

MRTX

1 minute read

Pinterest, Oracle And Some Other Big Stocks Moving Higher In Today’s Pre-Market Session

By Lisa Levin

Today, 9:10 PM

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. ACM Research, Inc. (NASDAQ: ACMR) shares jumped 25.9% to $10.98 in pre-market trading.

ABCL

8 minute read

Reported Late Monday, Mirati Therapeutics Announces U.S. FDA Accelerated Approval Of KRAZATI As A Targeted Treatment Option For Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer With A KRASG12C Mutation

By Benzinga Newsdesk

Today, 9:10 PM

Mirati Therapeutics, Inc. (NASDAQ:MRTX), a targeted oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRAZATI™ (adagrasib),

MRTX